Dr. S. Sundaresan has been working in the field of cancer chemoprevention, cancer immunotherapy, and tumor marker detection. Translational research (TR) has been described as translating research into medical practice and translating science into better healthcare. Translational research on tumor biomarkers has successfully promoted the development of tumor treatment and has brought new hope for cancer patients. It is important to direct cancer research on diagnosis and treatment toward applying fundamental research findings to the clinic as soon as possible, and applying novel tumor molecular markers to early diagnosis, targeted therapy, and individualized treatment. Focused medical treatment should be given through the analysis of new tumor biomarkers and appropriate treatments. Dr. S. Sundaresan has been working with oral cancer and cancer biomarkers. There are newer molecular markers that are of clinical significance and they need to be studied in various populations. The administration of indoles and triterpenes for preventive and curative effects was studied in laboratory animals. Dr. S. Sundaresan’s research study also demonstrates interferon beta synergistically works with chemotherapeutic drug cisplatin for liver, breast, and cervix cancer cells.